{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:59:09Z","timestamp":1765486749061},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00108-022-01287-y","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T15:09:28Z","timestamp":1647616168000},"page":"388-396","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapie der parenteral \u00fcbertragbaren Virushepatitiden"],"prefix":"10.1007","volume":"63","author":[{"given":"Elena","family":"Durmashkina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"1287_CR1","first-page":"3","volume":"28","author":"RKI","year":"2021","unstructured":"RKI (2021) Epidemiol Bull 28:3\u201319","journal-title":"Epidemiol Bull"},{"key":"1287_CR2","first-page":"3","volume":"29","author":"RKI","year":"2021","unstructured":"RKI (2021) Epidemiol Bull 29:3\u201321","journal-title":"Epidemiol Bull"},{"key":"1287_CR3","unstructured":"https:\/\/www.who.int\/hepatitis\/publications\/hep-eliminationby-2030-brief\/en\/. Zugegriffen: 10.12.2021"},{"key":"1287_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1055\/a-1226-0241","volume":"58","author":"C Sarrazin","year":"2020","unstructured":"Sarrazin\u00a0C et\u00a0al (2020) Prophylaxe, Diagnostik und Therapie der Hepatitis C. Z\u00a0Gastroenterol 58:1110\u20131131","journal-title":"Z Gastroenterol"},{"key":"1287_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"Cornberg M et al. S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie","year":"2021","unstructured":"Cornberg M et al. S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie (2021) Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z\u00a0Gastroenterol 59:691\u2013776","journal-title":"Z Gastroenterol"},{"issue":"5\u20136","key":"1287_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00103-013-1673-x","volume":"56","author":"C Poethko-Muller","year":"2013","unstructured":"Poethko-Muller\u00a0C, Zimmermann\u00a0R, Hamouda\u00a0O et al (2013) Die Seroepidemiologie der Hepatitis A, B und C in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt 56(5\u20136):707\u2013715","journal-title":"Bundesgesundheitsblatt"},{"key":"1287_CR7","first-page":"32","volume":"1","author":"W Gerlich","year":"2012","unstructured":"Gerlich\u00a0W, Glebe\u00a0D, Sch\u00fcttler\u00a0C (2012) Infektiosit\u00e4t des Hepatitis B Virus. Hepat More 1:32\u201341","journal-title":"Hepat More"},{"key":"1287_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","volume":"151","author":"BJ McMahon","year":"1985","unstructured":"McMahon\u00a0BJ, Alward\u00a0WL, Hall\u00a0DB et\u00a0al (1985) Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J\u00a0Infect Dis 151:599\u2013603","journal-title":"J Infect Dis"},{"key":"1287_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cld.2004.02.003","volume":"8","author":"SH Han","year":"2004","unstructured":"Han\u00a0SH (2004) Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis 8:403\u2013418","journal-title":"Clin Liver Dis"},{"key":"1287_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL Clinical practice guidelines: management of chronic hepatitis B. J\u00a0Hepatol 67:370\u2013398","journal-title":"J Hepatol"},{"key":"1287_CR11","volume-title":"Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie","author":"E Mutschler","year":"2008","unstructured":"Mutschler\u00a0E, Geisslinger\u00a0G, Kroemer\u00a0HK, Ruth\u00a0P, Sch\u00e4fer-Korting\u00a0M (2008) Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie, 9.\u00a0Aufl. Wissenschaftliche Verlagsgesellschaft, Stuttgart","edition":"9"},{"key":"1287_CR12","doi-asserted-by":"publisher","first-page":"313A","DOI":"10.1002\/hep.27486","volume":"60","author":"P Marcellin","year":"2014","unstructured":"Marcellin\u00a0P et\u00a0al (2014) Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8\u00a0year results from two phase 3 trials. Hepatology 60:313A\u2013317A","journal-title":"Hepatology"},{"key":"1287_CR13","unstructured":"EMA Zusammenfassung der Merkmale des Arzneimittels Viread.  https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/viread. Zugegriffen: 10.12.2021"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Butti","year":"2016","unstructured":"Butti\u00a0M et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1:196\u2013206","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1287_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"L Chan","year":"2016","unstructured":"Chan\u00a0L et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1(3):185\u2013195","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"1287_CR16","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1592\/phco.26.12.1745","volume":"26","author":"KA Sims","year":"2006","unstructured":"Sims\u00a0KA, Woodland\u00a0AM (2006) Entecavir: a\u00a0new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy 26(12):1745\u20131757","journal-title":"Pharmacotherapy"},{"key":"1287_CR17","unstructured":"Fachinformation Baraclude\u00ae 0,5\u202fmg\/1\u202fmg Filmtabletten"},{"issue":"5","key":"1287_CR18","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"Th Berg","year":"2017","unstructured":"Berg\u00a0Th et\u00a0al (2017) Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u00a0\u2013 FINITE study. J Hepatol 67(5):918\u2013924","journal-title":"J Hepatol"},{"key":"1287_CR19","unstructured":"EMA Zusammenfassung der Merkmale des Arzneimittels Hepcludex.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hepcludex-epar-product-information_de.pdf. Zugegriffen: 10.12.2021"},{"key":"1287_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/a-0599-1320","volume":"56","author":"C Sarrazin","year":"2018","unstructured":"Sarrazin\u00a0C, Zimmermann\u00a0T et al (2018) S3-Leitlinie \u201eProphylaxe, Diagnostik. Z\u00a0Gastroenterol 56:756\u2013838","journal-title":"Z Gastroenterol"},{"key":"1287_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1055\/s-0042-107360","volume":"54","author":"T Zimmermann","year":"2016","unstructured":"Zimmermann\u00a0T, Beckebaum\u00a0S, Berg\u00a0C et\u00a0al (2016) Expert recommendations: Hepatitis C and transplantation. Z\u00a0Gastroenterol 54:665\u2013684","journal-title":"Z Gastroenterol"},{"key":"1287_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MC Cheung","year":"2016","unstructured":"Cheung\u00a0MC, Walker\u00a0AJ, Hudson\u00a0BE et al (2016) Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J\u00a0Hepatol 65:741\u2013747","journal-title":"J Hepatol"},{"issue":"1\u20132","key":"1287_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3238\/arztebl.2017.0011","volume":"114","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem\u00a0S (2017) Therapieoptionen bei Hepatitis C. Dtsch Arztebl Int 114(1\u20132):11\u201320. https:\/\/doi.org\/10.3238\/arztebl.2017.0011","journal-title":"Dtsch Arztebl Int"},{"key":"1287_CR24","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Zepatier (Fachinformation).  http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/004126\/WC500211235.pdf. Zugegriffen: 10.12.2021"},{"key":"1287_CR25","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Epclusa (Fachinformation).  http:\/\/ec.europa.eu\/health\/documents\/communityregister\/2016\/20160706135323\/anx_135323_de.pdf. Zugegriffen: 10.12.2021"},{"key":"1287_CR26","volume-title":"Efficacy of SOF\/VEL for 12 Weeks in GT 1\u20136 Patients With and Without Cirrhosis (Integrated Analysis)","author":"K Agarwal","year":"2016","unstructured":"Agarwal\u00a0K et al (2016) Efficacy of SOF\/VEL for 12 Weeks in GT 1\u20136 Patients With and Without Cirrhosis (Integrated Analysis). EASL 2016. (Poster #SAT-195)"},{"key":"1287_CR27","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld\u00a0JJ et\u00a0al (2015) Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N\u00a0Engl J Med 373:2599\u20132607","journal-title":"N Engl J Med"},{"key":"1287_CR28","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Maviret (Fachinformation).  https:\/\/ec.europa.eu\/health\/documents\/communityregister\/2017\/20170726138539\/anx_138539_de.pdf. Zugegriffen: 10.12.2021"},{"issue":"Suppl","key":"1287_CR29","doi-asserted-by":"publisher","first-page":"S721","DOI":"10.1016\/S0168-8278(17)31927-X","volume":"66","author":"M Puoti","year":"2017","unstructured":"Puoti\u00a0M et\u00a0al (2017) Glecaprevir\/Pibrentasvir in Patients with Hepatitis C. J\u00a0Hepatol 66(Suppl):S721","journal-title":"J Hepatol"},{"key":"1287_CR30","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Vosevi (Fachinformation).  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vosevi-epar-product-information_de.pdf. Zugegriffen: 10.12.2021"},{"key":"1287_CR31","first-page":"33","volume":"1","author":"L Lou","year":"2013","unstructured":"Lou\u00a0L (2013) Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B. J\u00a0Clin Transl Hepatol 1:33\u201338","journal-title":"J Clin Transl Hepatol"},{"key":"1287_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"N Terrault","year":"2016","unstructured":"Terrault\u00a0N et\u00a0al (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63:261\u2013283","journal-title":"Hepatology"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01287-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T08:05:01Z","timestamp":1648195501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01287-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01287-y","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"1 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Durmashkina: Vortragst\u00e4tigkeiten f\u00fcr Gilead, Abbvie, Intercept. S.\u00a0Zeuzem: Berater- und\/oder Vortragst\u00e4tigkeiten f\u00fcr Abbvie, Allergan, BioMarin, Gilead, Intercept, Janssen, MSD, NovoNordisk, SoBi und Theratechnologies. C.\u00a0Sarrazin: Vortr\u00e4ge, Beratung und Forschungsunterst\u00fctzung durch Abbvie, Gilead und MSD\/Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}